Service of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.
Am J Cardiovasc Drugs. 2020 Feb;20(1):105-115. doi: 10.1007/s40256-019-00361-5.
American and European associations of cardiology published specific guidelines about recommended drugs for secondary prevention in ST-segment elevation myocardial infarction (STEMI) patients. Our aim was to assess whether drug prescription for STEMI patients was in accordance with the guidelines at discharge and after 1 year.
We used data of 361 patients admitted for STEMI in a tertiary hospital in Switzerland from 2014 to 2016. We assessed the adequacy of prescription of recommended drugs at two time points: discharge and after 1 year. Medications assessed were aspirin, P2Y12 inhibitors, statin, angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) and β-blockers. We took into account several criteria like statin dosage (low versus high intensity) and presence of contraindication for consideration of optimal therapy. Predictors of incomplete prescription of guideline medications were then assessed with multivariate logistic regression models.
From discharge (n = 358) to 1-year follow-up (n = 303), rate of optimal prescription was reduced from 98.6 to 91.7% for aspirin, from 93.9 to 79.1% for P2Y12 inhibitors, from 83.8 to 65.7% for statins, from 98.6 to 95.6% for ACEIs/ARBs, and from 97.1 to 96.9% for β-blockers. Predictors of incomplete prescription of guideline medications at discharge were female sex (odds ratio [OR] 2.54, p = 0.007), active or former smoker status (OR 2.29, p = 0.017), multivessel disease (OR 2.07, p = 0.022), left ventricular ejection fraction < 40% (OR 2.49, p = 0.008), and transfer to cardiac surgery (OR 9.66, p = 0.018). At 1 year, age > 65 (OR 1.92, p = 0.036) remained the only significant predictor.
The present study showed a high prescription rate of guideline-recommended medications in a referral center for primary percutaneous coronary intervention. At discharge, women and co-morbid patients were at the highest risk of incomplete prescription of guideline medications, whereas long-term prescription was suboptimal for elderly. A drug lacking at time of discharge was rarely introduced within the year, which underscores the paramount importance of optimal prescription at time of discharge. Strategies like implementing a standardized prescription could reduce the proportion of suboptimal prescription. It could therefore be one way to improve the long-term quality of care of our patients to the highest level. This study used local data from AMIS Plus-National Registry of Acute Myocardial Infarction in Switzerland (NCT01305785).
美国和欧洲心脏病学会发布了关于 ST 段抬高型心肌梗死(STEMI)患者二级预防推荐药物的具体指南。我们的目的是评估 STEMI 患者出院时和出院后 1 年时的药物处方是否符合指南。
我们使用了 2014 年至 2016 年瑞士一家三级医院收治的 361 例 STEMI 患者的数据。我们评估了在两个时间点推荐药物处方的适当性:出院时和出院后 1 年。评估的药物包括阿司匹林、P2Y12 抑制剂、他汀类药物、血管紧张素转换酶抑制剂(ACEI)/血管紧张素受体阻滞剂(ARB)和β受体阻滞剂。我们考虑了他汀类药物剂量(低强度与高强度)和存在禁忌证等几个标准,以考虑最佳治疗方案。然后使用多变量逻辑回归模型评估指南药物不完全处方的预测因素。
从出院(n=358)到 1 年随访(n=303),阿司匹林的最佳处方率从 98.6%降至 91.7%,P2Y12 抑制剂从 93.9%降至 79.1%,他汀类药物从 83.8%降至 65.7%,ACEI/ARB 从 98.6%降至 95.6%,β受体阻滞剂从 97.1%降至 96.9%。出院时指南药物不完全处方的预测因素为女性(比值比[OR] 2.54,p=0.007)、现吸烟者或既往吸烟者(OR 2.29,p=0.017)、多血管疾病(OR 2.07,p=0.022)、左心室射血分数<40%(OR 2.49,p=0.008)和转至心脏手术(OR 9.66,p=0.018)。1 年后,年龄>65 岁(OR 1.92,p=0.036)仍然是唯一有显著意义的预测因素。
本研究显示,在经皮冠状动脉介入治疗的转诊中心,指南推荐的药物处方率很高。出院时,女性和合并症患者最有可能出现指南药物处方不完全的情况,而长期处方对老年人则不太理想。出院时缺少的药物在 1 年内很少被引入,这突出表明出院时的最佳处方至关重要。实施标准化处方等策略可以降低处方不理想的比例。因此,这可能是将患者的长期护理质量提高到最高水平的一种方式。本研究使用了来自瑞士 AMIS Plus-急性心肌梗死国家登记处(NCT01305785)的本地数据。